Briquilimab Shows Promising Results in Chronic Urticaria Studies
Jasper Therapeutics has reported updated data from its BEACON Phase 1b/2a study of briquilimab, a subcutaneous antibody therapy for...
Bezuclastinib Shows Positive Top-Line Results in Summit Trial
Cogent Biosciences announced positive top-line results from its SUMMIT clinical trial of bezuclastinib for non-advanced systemic mastocytosis (NonAdvSM). The...
Plinabulin Boosts Dendritic Cell Growth, Fights Tumors After Checkpoint Inhibitor Failure
A recent study published in •Med• revealed that Plinabulin, in combination with radiation and PD-1 inhibitors, shows promise in...
Ashvattha Therapeutics Positive Interim Phase 2 Results for DME and Wet-AMD
Ashvattha Therapeutics announced interim Phase 2 trial results for its subcutaneous migaldendranib (MGB), a potential treatment for diabetic macular...
Chemomab Announces Positive Nebokitug Phase 2 Clinical Data in PSC at BSG ‘25
Chemomab Therapeutics announced positive Phase 2 SPRING trial data for nebokitug (CM-101) in patients with primary sclerosing cholangitis (PSC)...
Corbus Pharmaceuticals Initiates Phase 1 Study of CRB-913 for Obesity Treatment
Corbus Pharmaceuticals has initiated the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, an obesity...
Assembly Biosciences Doses First Participant in Phase 1b Trial of Herpes Simplex Virus Inhibitor
Assembly Biosciences has dosed the first participant in a Phase 1b study of ABI-1179, an oral, long-acting herpes simplex...
Magic Catheter Study’s First Clinical Results Published
Stereotaxis announced the publication of initial clinical results for its MAGiC robotic magnetic navigation ablation catheter in the Journal...
Leronlimab Shows Encouraging Survival Data in Metastatic Colorectal Cancer Patients
CytoDyn announced encouraging clinical findings from a compassionate use study of leronlimab in patients with advanced metastatic colorectal cancer...
Zervimesine Alzheimer’s Study Surpasses 50% Enrollment
Cognition Therapeutics announced that its Phase 2 START Study for Alzheimer’s disease has surpassed 50% enrollment. The study, conducted...